MV BioTherapeutics SA products

SNP-apyrase for oral use in the treatment of IBD • Lead compound, MV010, has shown animal PoC in a murine model of ulcerative colitis. • Abrogation of the pro-inflammatory function of extracellular ATP in the intestine without systemic immune suppression. • Amplification of secretory IgA production in Peyer's patches and gut-associated lymphoid tissue (GALT), ensuring high specificity for individual immune regulation. • Promotion of a healthy microbiome by enhancing the binding of secretory IgA to bacterial antigens, thereby reducing dysbiosis—a key factor in IBD. • Absence of systemic side effects compared to standard of care by limiting the pharmacological action of apyrase to the gut and implementing the gut-specific function of IgA • Easy extension to other dysbiotic conditions such as Crohn’s Disease, Dysbiosis and others.

MV010/MV004, in cancer immunotherapy • Significant increase of tumor specific cytotoxic T cells infiltrating the tumor microenvironment by combining MV010/MV004 to anti-PD-L1 administration in murine models. • Significantly improved tumor eradication and resistance to subsequent grafting and improved survival in murine models.